公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV | CHUN-JEN LIU ; Chuang W.-L.; Sheen I.-S.; Wang H.-Y.; Chen C.-Y.; Tseng K.-C.; Chang T.-T.; Massetto B.; Yang J.C.; Yun C.; Knox S.J.; Osinusi A.; Camus G.; Jiang D.; Brainard D.M.; McHutchison J.G.; Hu T.-H.; Hsu Y.-C.; Lo G.-H.; Chu C.-J.; Chen J.-J.; Peng C.-Y.; Chien R.-N.; PEI-JER CHEN | Gastroenterology | 95 | 82 | |
2016 | Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus | Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 24 | 20 | |
2018 | Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study | Kudo M.; ANN-LII CHENG ; Park J.-W.; Park J.H.; PO-CHIN LIANG ; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. | The Lancet Gastroenterology and Hepatology | 126 | 114 | |
2016 | A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection | JIA-HORNG KAO ; Chien R.-N.; Chang T.-T.; Peng C.-Y.; Hu T.-H.; Lo G.-H.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Han L.; Mo H.; Mathias A.; Brainard D.M.; Sheen I.-S.; Hsu Y.-C.; Chu C.-J.; Chuang W.-L. | Liver International | 25 | 25 | |
1997 | Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers | MING-WHEI YU ; Hsu F.-C.; Sheen I.-S.; Chu C.-M.; Lin D.-Y.; Chen C.-J.; Liaw Y.-F. | American Journal of Epidemiology | 267 | 234 | |
2010 | A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients | Yang T.-S.; Lu S.-N.; Chao Y.; Sheen I.-S.; Lin C.-C.; Wang T.-E.; Chen S.-C.; Wang J.-H.; Liao L.-Y.; Thomson J.A.; Wang-Peng J.; PEI-JER CHEN ; Chen L.-T. | British Journal of Cancer | 134 | 124 | |
2016 | Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis | JIA-HORNG KAO ; Tung S.-Y.; Lee Y.; Thongsawat S.; Tanwandee T.; Sheen I.-S.; Wu J.J.; Li H.; Brennan B.J.; Zhou J.; Le Pogam S.; Najera I.; Thommes J.A.; Hill G. | Journal of Gastroenterology and Hepatology (Australia) | 10 | 7 | |
2015 | Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study | ANN-LII CHENG ; Kang Y.-K.; He A.R.; Lim H.Y.; Ryoo B.-Y.; Hung C.-H.; Sheen I.-S.; Izumi N.; Austin T.; Wang Q.; Greenberg J.; Shiratori S.; Beckman R.A.; Kudo M. | Journal of Hepatology | 39 | 42 |